Last reviewed · How we verify

irbesartan, amlodipine and hydrochlorothiazide

Assistance Publique - Hôpitaux de Paris · FDA-approved active Small molecule

irbesartan, amlodipine and hydrochlorothiazide is a Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently FDA-approved for Hypertension (essential hypertension in patients requiring combination therapy).

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium and water excretion.

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium and water excretion. Used for Hypertension (essential hypertension in patients requiring combination therapy).

At a glance

Generic nameirbesartan, amlodipine and hydrochlorothiazide
SponsorAssistance Publique - Hôpitaux de Paris
Drug classAntihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)
TargetAngiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Irbesartan is an angiotensin II receptor blocker (ARB) that prevents vasoconstriction and aldosterone release. Amlodipine is a calcium channel blocker that relaxes vascular smooth muscle. Hydrochlorothiazide is a thiazide diuretic that reduces blood volume and sodium reabsorption. Together, these agents provide synergistic blood pressure reduction through distinct pathways.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about irbesartan, amlodipine and hydrochlorothiazide

What is irbesartan, amlodipine and hydrochlorothiazide?

irbesartan, amlodipine and hydrochlorothiazide is a Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Hypertension (essential hypertension in patients requiring combination therapy).

How does irbesartan, amlodipine and hydrochlorothiazide work?

This triple-combination antihypertensive reduces blood pressure through three complementary mechanisms: blocking angiotensin II receptors, inhibiting calcium influx into vascular smooth muscle, and promoting sodium and water excretion.

What is irbesartan, amlodipine and hydrochlorothiazide used for?

irbesartan, amlodipine and hydrochlorothiazide is indicated for Hypertension (essential hypertension in patients requiring combination therapy).

Who makes irbesartan, amlodipine and hydrochlorothiazide?

irbesartan, amlodipine and hydrochlorothiazide is developed and marketed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

What drug class is irbesartan, amlodipine and hydrochlorothiazide in?

irbesartan, amlodipine and hydrochlorothiazide belongs to the Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) class. See all Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) drugs at /class/antihypertensive-combination-arb-calcium-channel-blocker-thiazide-diuretic.

What development phase is irbesartan, amlodipine and hydrochlorothiazide in?

irbesartan, amlodipine and hydrochlorothiazide is FDA-approved (marketed).

What are the side effects of irbesartan, amlodipine and hydrochlorothiazide?

Common side effects of irbesartan, amlodipine and hydrochlorothiazide include Dizziness, Fatigue, Headache, Hyperuricemia, Hypokalemia, Cough.

What does irbesartan, amlodipine and hydrochlorothiazide target?

irbesartan, amlodipine and hydrochlorothiazide targets Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter and is a Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic).

Related